After taxane and anthracycline failure, no standard chemotherapy regimen is established in metastatic breast cancer (MBC). Capecitabine and cisplatin (XP) combination shows promising results in gastrointestinal cancer, but there are relatively scarce data in MBC. We reviewed the clinical outcome of XP regimen in anthracycline and taxane resistant, heavily pretreated MBC patients. IV; day 1], every 3 weeks) regimen.Median progression-free survival (PFS) in total population was 4.33 months (range 1.1~33.57 months). HR positive patients showed trends for superior PFS compared to triple negative breast cancer (TNBC), without statistical significance (6.53 vs. 3.83 months, P = 0.168). In HR positive group, patients receiving 3 or less lines of c...
Anthracyclines and taxanes are active cytotoxic drugs in the treatment of early metastatic breast ca...
Anthracyclines and taxanes are active cytotoxic drugs in the treatment of early metastatic breast ca...
This study was aimed to establish clinical efficacy and tolerability of gemcitabine and cisplatin co...
PURPOSE/OBJECTIVE(S):After taxane and anthracycline failure, no standard chemotherapy regimen is est...
BACKGROUND: Treating patients with anthracycline- and taxane-pretreated metastatic breast cancer is ...
Currently, there is no standard treatment for patients with anthracycline and taxane-refractory meta...
Background: The most commonly used chemotherapeutic regimens in the treatment of metastatic breast c...
Patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes ofte...
Due to the limited experience with capecitabine plus docetaxel (XT) combination in the first-line tr...
Due to the limited experience with capecitabine plus docetaxel (XT) combination in the first-line tr...
Objective: To investigate the efficacy and safety of capecitabine maintenance therapy (MT) after ini...
International audiencePURPOSE: Effective treatment options for patients with metastatic breast cance...
Capecitabine is effective and indicated for the salvage treatment of metastatic breast cancer. There...
Metastatic breast cancers (MBC) previously treated with anthracyclines (A) and taxanes (T) have a co...
International audienceLimited proven treatment options exist for patients with metastatic breast can...
Anthracyclines and taxanes are active cytotoxic drugs in the treatment of early metastatic breast ca...
Anthracyclines and taxanes are active cytotoxic drugs in the treatment of early metastatic breast ca...
This study was aimed to establish clinical efficacy and tolerability of gemcitabine and cisplatin co...
PURPOSE/OBJECTIVE(S):After taxane and anthracycline failure, no standard chemotherapy regimen is est...
BACKGROUND: Treating patients with anthracycline- and taxane-pretreated metastatic breast cancer is ...
Currently, there is no standard treatment for patients with anthracycline and taxane-refractory meta...
Background: The most commonly used chemotherapeutic regimens in the treatment of metastatic breast c...
Patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes ofte...
Due to the limited experience with capecitabine plus docetaxel (XT) combination in the first-line tr...
Due to the limited experience with capecitabine plus docetaxel (XT) combination in the first-line tr...
Objective: To investigate the efficacy and safety of capecitabine maintenance therapy (MT) after ini...
International audiencePURPOSE: Effective treatment options for patients with metastatic breast cance...
Capecitabine is effective and indicated for the salvage treatment of metastatic breast cancer. There...
Metastatic breast cancers (MBC) previously treated with anthracyclines (A) and taxanes (T) have a co...
International audienceLimited proven treatment options exist for patients with metastatic breast can...
Anthracyclines and taxanes are active cytotoxic drugs in the treatment of early metastatic breast ca...
Anthracyclines and taxanes are active cytotoxic drugs in the treatment of early metastatic breast ca...
This study was aimed to establish clinical efficacy and tolerability of gemcitabine and cisplatin co...